Oncotarget

Research Papers:

Targeted delivery of nano-PTX to the brain tumor-associated macrophages

Lei Zou _, Youhua Tao, Gregory Payne, Linh Do, Tima Thomas, Juan Rodriguez and Huanyu Dou

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:6564-6578. https://doi.org/10.18632/oncotarget.14169

Metrics: PDF 1910 views  |   HTML 1794 views  |   ?  


Abstract

Lei Zou1, Youhua Tao1, Gregory Payne1, Linh Do1, Tima Thomas1, Juan Rodriguez1, Huanyu Dou1,2

1Department of Biomedical Sciences, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, Texas 79905, USA

2Graduate School of Biomedical Sciences, Texas Tech University Health Sciences Center El Paso, Texas 79905, USA

Correspondence to:

Huanyu Dou, email: huanyu.dou@ttuhsc.edu

Keywords: nanoparticles, brain targeted delivery, tumor associated macrophages, glioma

Received: October 07, 2015     Accepted: December 02, 2016     Published: December 25, 2016

ABSTRACT

Nanoparticles containing mixed lipid monolayer shell, biodegradable polymer core and rabies virus glycoprotein (RVG) peptide as brain targeting ligand, were developed for brain targeted delivery of paclitaxel (PTX) to treat malignant glioma. RVG conjugated PTX loaded NPs (RVG-PTX-NPs) had the desirable size (~140 nm), narrow size distribution and spherical shape. RVG-PTX-NPs showed poor uptake by neurons and selective targeting to the brain tumor associated macrophages (TAMs) with controlled release and tumor specific toxicity. In vivo studies revealed that RVG-PTX-NPs were significant to cross the blood-brain barrier (BBB) and had specific targeting to the brain. Most importantly, RVG-PTX-NPs showed effectiveness for anti-glioma therapy on human glioma of mice model. We concluded that RVG-PTX-NPs provided an effective approach for brain-TAMs targeted delivery for the treatment of glioma.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 14169